Stocks in Focus – Amgen Inc. (NASDAQ:AMGN)
Shares of Amgen Inc. (NASDAQ:AMGN) decreased 2.09% in final minutes of trading Thursday. The stock closed the last trade at $167.81, exchanging hands with 2578014 shares contrast to its average daily volume of 3.18M shares.
Two of the nation’s leading health organizations, health and well-being company Humana Inc. (HUM) and biotechnology company Amgen (AMGN), have teamed up to identify opportunities to improve health outcomes and improve efficiency by unlocking new insights from the real world health care experiences of Humana’s 13 million members.
In the partnership agreement between Amgen and Humana, six projects are presently underway or planned, with more predictable over the term of the agreement. Both organizations are committed to expanding the work into further therapeutic areas where the partnership can bring value to both Amgen and Humana. The aim is the same across all projects: deliver raised value to patients and the health care system by focusing on working to improve quality and outcomes in the context of total health care costs.
The partnership will, at first target multiple serious conditions, counting cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer. Researchers will combine available sources of real world evidence (RWE) with data from wearable technology, digital apps and Bluetooth-enabled drug delivery devices. Prospective observational studies are also planned.
Planned research will identify patients whose serious medical conditions are likely to result in an adverse patient outcome, which may lead to development of algorithms that can predict risk and drive to early intervention. The partnership will also dive deeply into specific therapeutic areas, from defining the burden of osteoporatic fractures to understanding the impact of wearable technology on medication adherence for inflammatory diseases.
“The rising cost of disease is challenging the sustainability of our health care system in the U.S., and is motivating innovators to urgently develop new therapeutic options and partner on opportunities to improve the quality and efficiency of care and reduce financial burden to the system,” said Joshua Ofman, M.D., M.S.H.S., senior vice president of Global Value, Access & Policy at Amgen. “It is our hope that this partnershipwith Humana, a first of its kind for Amgen, will cultivate value-based, integrated approaches to care that will focus on patients and benefit the healthcare system more broadly.”
“Humana is focused on the holistic health of our members and by teaming up with Amgen we can study new ways to improve the health outcomes for our members,” said Laura Happe, Pharm.D. M.P.H., chief pharmacy officer for Humana. “At the same time, we hope this research results in new tools and technology that support our provider partners who are on the journey to population health and value-based care.”
Amgen and Humana have proven experience in value-based programs. Globally, Amgen has engaged in more than 75 distinct value-based programs that have focused on improving clinical outcomes, patient experience and population health.
Stock’s Performance Analysis (Weekly, Monthly & Year to Date):
The stock, as of recent close, has shown weekly downbeat performance of 0.77% which was maintained at -6.35% in 1-month period, and is up 14.77% in this year. The company has the market capitalization of $123.17B while its P/B ratio was 3.88. Institutional investors own 81.1% stake in the company while Beta factor, which is used to measure riskiness of the security, was 1.36.
Stock’s Technical Analysis:
In taking a look at technical levels, shares are trading -3.8% away from the 20-days simple moving average and 3.69% away from the 200-days simple moving average. Based on a recent bid, the stock is trading -8.9% away from its 52-week high and 25.57% away from its 52 week low.
Relative Strength Index (RSI):
The relative strength index (RSI) is a technical indicator used in the analysis of financial markets. It is intended to chart the current and historical strength or weakness of a stock or market based on the closing prices of a recent trading period. The indicator should not be confused with relative strength.
The RSI is classified as a momentum oscillator, measuring the velocity and magnitude of directional price movements. Momentum is the rate of the rise or fall in price. The RSI computes momentum as the ratio of higher closes to lower closes: stocks which have had more or stronger positive changes have a higher RSI than stocks which have had more or stronger negative changes.
The RSI is most typically used on a 14-day timeframe, measured on a scale from 0 to 100, with high and low levels marked at 70 and 30, respectively. Shorter or longer timeframes are used for alternately shorter or longer outlooks. More extreme high and low levels—80 and 20, or 90 and 10—occur less frequently but indicate stronger momentum. After a recent check, Amgen Inc.’s 14-day RSI is presently at 38.85.
Analysts’ Suggestions in the Limelight:
The stock received analysts’ mean target price of $187.21. This is the projected price level of a financial security stated by an investment analyst or advisor. Shareholders can make better decisions if they focus on target prices, which convey more information for evaluating the potential risk/reward profile of a stock. However, analysts’ mean recommendation for this stock stands at 2.4. Analyst recommendations as stated on FINVIZ are rated on a 1 to 5 scale. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. The consensus recommendation is the average rating on a stock by the analyst community.
